When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
François Prince(Hôpital du Sacré-Cœur de Montréal), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), S. S. M. Kamphuis(Erasmus MC - Sophia Children’s Hospital), Marinka Twilt(University of Calgary), Nico Wulffraat(Utrecht University), R. ten Cate(Leiden University), Esther P A H Hoppenreijs(Radboud University Nijmegen), M van Santen-Hoeufft(Maastricht University Medical Centre), Wineke Armbrust, Marion A. J. van Rossum(Reade), Y. Koopman-Keemink(Juliana Kinderziekenhuis), S C M Simon(Erasmus MC - Sophia Children’s Hospital)
Cited by 42
Related Papers
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome
|Nature Genetics|2000|951
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
|The Lancet Child & Adolescent Health|2019|214